(Total Views: 743)
Posted On: 10/08/2020 4:25:49 PM
Post# of 154977
Re: invisioner #60442
“Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) are sharing additional data showing baricitinib in combination with remdesivir.”
NP once mentioned long ago that there was an offer to combine leronlimab with remdesevir in a trial. Personally, at the time and now, I was for a combined trial because the other entity (NIH, BP, hospital, etc.) would help with funding and the trial would’ve likely been enrolled quicker.
Let’s get these S/C trial results out and compete with these other companies.
NP once mentioned long ago that there was an offer to combine leronlimab with remdesevir in a trial. Personally, at the time and now, I was for a combined trial because the other entity (NIH, BP, hospital, etc.) would help with funding and the trial would’ve likely been enrolled quicker.
Let’s get these S/C trial results out and compete with these other companies.
(3)
(0)
